Core Viewpoint - The company plans to sign a cooperation research and development agreement with Huazhong Agricultural University, which is expected to enhance its core competitiveness in the bioproducts sector and accelerate its development in the industry [1]. Summary by Relevant Sections - **Cooperation Agreement**: The proposed agreement with Huazhong Agricultural University is seen as beneficial for improving the company's competitiveness in the bioproducts field [1]. - **Compliance and Procedures**: The transaction adheres to the company's articles of association, cooperation research and development management system, and the framework agreement with Huazhong Agricultural University, ensuring that all procedures are followed [1]. - **Related Party Transaction**: This transaction is classified as a related party transaction, with legal voting procedures and fair pricing, ensuring no harm to the company or its shareholders [1].

辽宁成大生物股份有限公司 投资者关系管理制度 辽宁成大生物股份有限公司 投资者关系管理制度 第一章 总则 第一条 为加强辽宁成大生物股份有限公司（以下简称"公司"）与投资者和 潜在投资者（以下简称"投资者"）之间的信息沟通，增进投资者对公司的了解与 认同，切实维护广大投资者的合法权益，完善公司的治理结构，根据《中华人民共 和国公司法》 （以下简称"《公司法》"） 《中华人民共和国证券法》 （以下简称"《证 券法》"） 《上市公司治理准则》 《上市公司投资者关系管理工作指引》 《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号 ——规范运作》等法律、法规和规范性文件的规定及《辽宁成大生物股份有限公司 章程》（以下简称"《公司章程》" ），结合公司实际情况，制定本制度。 第二条 本制度所称投资者关系管理是指公司通过便利股东权利行使、信息披 露、互动交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投 资者对公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、 回报投资者、保护投资者目的的相关活动。 第三条 公司投资者关系管理工作应严格遵守《公司法 ...

辽宁成大生物股份有限公司 募集资金管理制度 第一章 总则 辽宁成大生物股份有限公司 募集资金管理制度 公司董事会办公室负责与募集资金管理、使用及变更有关的信息披露；财务 部门负责募集资金的日常管理，包括专用账户的开立及管理，募集资金的存放、 使用和台账管理。 第五条 公司控股股东、实际控制人不得直接或者间接占用或者挪用公司募 集资金，不得利用公司募投项目获取不正当利益。 公司发现控股股东、实际控制人及其他关联人占用募集资金的，应当及时要 求归还，并披露占用发生的原因、对公司的影响、清偿整改方案及整改进展情况。 第一条 为规范辽宁成大生物股份有限公司（以下简称"公司"）募集资金 的使用与管理，提高募集资金使用效益，保护投资者的合法权益，根据《中华人 民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以 下简称"《证券法》"）《上市公司治理准则》《上市公司募集资金监管规则》 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等法律、法规和规范性文件的规定及《辽宁成大 生物股份有限公司章程》（以下简称"《公司章程》"），结合公司实际情况， 制定 ...

辽宁成大生物股份有限公司 董事、高级管理人员持股变动管理办法 董事、高级管理人员持股变动管理办法 第一章 总则 第一条 为加强辽宁成大生物股份有限公司（以下简称"公司"或"本公司"） 对董事、高级管理人员持有及买卖本公司股份的管理工作，根据《中华人民共和 国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称 "《证券法》"）《上市公司股东减持股份管理暂行办法》《上市公司董事和高 级管理人员所持本公司股份及其变动管理规则》《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》《上海证券交易所上市公司自律监管指引 第 8 号——股份变动管理》《上海证券交易所上市公司自律监管指引第 15 号— —股东及董事、高级管理人员减持股份》等法律、行政法规、部门规章、规范性 文件及《辽宁成大生物股份有限公司章程》（以下简称"《公司章程》"）的有 关规定，结合公司实际情况，制定本办法。 第二条 本办法适用于公司董事、高级管理人员所持本公司股份及其变动的 管理。 公司董事、高级管理人员所持本公司股份，是指登记在其名下和利用他人账 户持有的所有本公司股份。董事、高级管理人员拥有多个证券账户的，应当合 ...

Core Viewpoint - The document outlines the external guarantee management system of Liaoning Chengda Biological Co., Ltd., aiming to standardize external guarantee behaviors and effectively prevent related risks [1][2]. Chapter Summaries Chapter 1: General Principles - The system is established based on various laws and regulations to regulate the company's external guarantee behavior [1]. Chapter 2: Guarantee Principles - External guarantees refer to the company and its subsidiaries providing guarantees based on legal agreements, adhering to principles of fairness, voluntariness, and mutual benefit [2]. - The scope of this system includes the company and its subsidiaries [1]. Chapter 3: Guarantee Approval Management - All guarantees must be managed centrally by the company, requiring approval from the board of directors or shareholders before any guarantee is provided [2][3]. - Guarantees for related parties must have reasonable commercial logic and require disclosure and shareholder approval [2]. Chapter 4: Contract Signing - After board or shareholder approval, the chairman or other senior management is authorized to sign guarantee contracts [4][6]. - Guarantee contracts must comply with legal norms and clearly define the terms [6]. Chapter 5: Guarantee Risk Management - The board and finance department are responsible for managing and reviewing guarantee behaviors [7]. - Any abnormal contracts not approved by the board must be reported immediately [7]. Chapter 6: Accountability - Directors and managers who violate the established procedures for signing guarantee contracts may face economic and legal consequences [8]. - Individuals who fail to perform their duties, causing losses to the company, may be subject to penalties [8]. Chapter 7: Supplementary Provisions - Any matters not covered by this system or conflicting with legal requirements will be executed according to relevant laws and regulations [8].

Summary of Key Points Core Viewpoint - The company intends to utilize idle raised funds for cash management to enhance fund efficiency and shareholder returns while ensuring that it does not affect the ongoing investment projects or the normal operations of the company [1][6]. Group 1: Fundraising and Usage - The company raised a total of RMB 1,227.45 million from its initial public offering (IPO) by issuing 105 million shares at a price of RMB 11.69 per share, with a net amount of RMB 1,141.73 million after deducting issuance costs of RMB 85.72 million [1][2]. - The total investment amount for the projects funded by the IPO is RMB 1,799.19 million, with RMB 1,747.03 million allocated from the raised funds [2]. - Due to a lower-than-expected net amount from the IPO, the company adjusted its investment projects, excluding certain projects and reallocating funds to ensure efficient use [2][3]. Group 2: Cash Management Plan - The company plans to use up to RMB 260 million of idle raised funds for cash management, ensuring that it does not impact the investment projects or the company's operations [3][5]. - The investment period for the cash management is valid for 12 months from the board's approval date, with a focus on low-risk, high-liquidity investment products [3][4]. - The income generated from cash management will be used to supplement any shortfall in the investment amounts for the projects and will be returned to the raised funds account upon maturity [4][6]. Group 3: Impact on Operations - The cash management of idle funds is expected to improve the efficiency of fund usage without affecting the normal progress of investment projects or the company's core business [4][6]. - By managing idle funds effectively, the company aims to achieve additional investment returns, thereby enhancing overall performance and providing greater returns to shareholders [4][6]. Group 4: Compliance and Approval - The cash management plan has been approved by the company's board and supervisory board, complying with relevant laws and regulations [5][6]. - The company will adhere to strict risk control measures and disclose information as required by regulatory authorities [4][6].

General Principles - The rules are established to protect shareholders' rights and ensure the orderly conduct and efficiency of shareholder meetings [1] - The shareholder meeting is the company's decision-making body, composed of all shareholders [1][2] - The company must convene shareholder meetings in accordance with laws, regulations, and its articles of association [1][2] Types of Meetings - There are annual and temporary shareholder meetings; the annual meeting must be held within six months after the end of the previous fiscal year [2] - Temporary meetings must be held within two months under certain conditions, such as insufficient directors or significant losses [2][3] Meeting Convening - The board of directors is responsible for convening meetings within the specified time frame [3][4] - Independent directors and the audit committee can propose temporary meetings, requiring majority consent from independent directors [3][4] Proposals and Notifications - Shareholders holding more than 10% of shares can request a temporary meeting, and the board must respond within ten days [4][5] - Proposals for meetings must be submitted in writing and should align with the company's articles of association [6][16] Meeting Procedures - Shareholder meetings must be held at designated locations, and changes require prior notice [28] - The company must provide necessary facilities for shareholders to participate, including online voting options [29][30] Voting and Resolutions - Resolutions can be ordinary or special; ordinary resolutions require a simple majority, while special resolutions require a two-thirds majority [56][58] - Voting rights are based on the number of shares held, with each share granting one vote [59] Record Keeping - Meeting minutes must be recorded, detailing the time, location, attendees, and voting results [53][54] - The company must ensure that resolutions are announced promptly, including details of the voting results [70][72] Legal Compliance - Any violations of laws or regulations during the meeting can lead to legal challenges within 60 days [27] - The board and relevant parties must execute resolutions promptly and comply with disclosure obligations [27][28]

辽宁成大生物股份有限公司 内部审计制度 第四条 公司董事会审计委员会对内部审计制度的建立健全和有效实施负责，并保 证内部审计相关信息披露内容的真实、准确、完整。 第二章 内部审计机构及人员 第五条 公司董事会设立审计委员会。审计委员会成员为 3 名，为不在公司担任高 级管理人员的董事，其中独立董事 2 名，由独立董事会计专业人士担任召集人。 第六条 公司设置内部审计部门，对公司业务活动、风险管理、内部控制、财务信 息等事项进行监督检查。内部审计部门向审计委员会报告工作。内部审计部门在监督 检查过程中，应当接受审计委员会的监督指导，发现公司重大问题或线索，应当立即 向审计委员会直接报告。 辽宁成大生物股份有限公司 内部审计制度 内部审计部门应当保持独立性，配备专职审计人员，不得置于其他部门的领导之 下，或者与其他部门合署办公。 辽宁成大生物股份有限公司 内部审计制度 第一章 总 则 第一条 为规范辽宁成大生物股份有限公司(以下简称"公司")内部审计工作，加 强公司内部审计监督，防范经营风险，保护投资者的合法权益，根据《中华人民共和 国审计法》《审计署关于内部审计工作的规定》《上海证券交易所科创板上市公司自 律监 ...

Core Points - The document outlines the rules for the board of directors of Liaoning Chengda Biological Co., Ltd, aiming to standardize the decision-making process and enhance the board's operational efficiency [2][3] - The board is required to hold at least two regular meetings annually, with provisions for calling temporary meetings under specific circumstances [4][6] - The rules emphasize the importance of clear communication and documentation, including the necessity for written proposals and meeting notifications [8][10] Group 1 - The board of directors is responsible for making decisions within the scope defined by the company's articles of association and relevant laws [2][3] - The board office handles daily affairs and is responsible for maintaining the board's seal [2] - Proposals for meetings must be submitted in writing, detailing the proposer’s identity and the content of the proposal [6][8] Group 2 - Meetings require the presence of more than half of the directors to be valid, and provisions are made for directors to attend via telecommunication if necessary [11][14] - Directors must personally attend meetings or delegate their voting rights through a written proxy if unable to attend [12][13] - The board must ensure that decisions are made based on thorough discussions and that all relevant factors are considered [8][9] Group 3 - The board is required to review periodic reports carefully, ensuring accuracy and completeness, and must disclose any significant issues [17][20] - Decisions made by the board must receive approval from more than half of the directors present, with specific rules for related party transactions [24][25] - The board is mandated to maintain confidentiality regarding decisions until they are officially disclosed [30][32]

Core Points - Liaoning Chengda Biotechnology Co., Ltd. was established as a joint-stock company in accordance with the Company Law and other relevant regulations [1] - The company completed its initial public offering of 41.65 million shares on October 28, 2021, after approval from the Shanghai Stock Exchange [1][3] - The registered capital of the company is RMB 416.45 million [1] - The company is committed to the research, development, production, and promotion of biological products, adhering to the core values of integrity, responsibility, and quality control [1][2] Company Structure and Governance - The company is governed by a board of directors, with the chairman serving as the legal representative [1] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with its entire assets [1] - The company has established procedures for external guarantees and related party transactions, requiring board or shareholder approval [1][2] Share Issuance and Management - The company's shares are issued in the form of stocks, with each share having a par value of RMB 1 [3][5] - The total number of shares issued at the time of establishment was 360 million, with the current total being 41.65 million shares [5] - The company has specific regulations regarding the increase, decrease, and repurchase of shares, requiring shareholder approval for significant transactions [5][6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company decisions, as well as the right to inspect company documents [9][10] - The company must hold annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [25][26] - Shareholders holding more than 3% of shares for over 180 days can request access to the company's accounting records [10] Financial Management and Transactions - The company must submit significant transactions, including guarantees and financial assistance, for shareholder approval [51][52] - Transactions involving related parties that exceed certain thresholds require evaluation and approval [53][54] - The company is prohibited from providing financial assistance for the acquisition of its shares, except under specific conditions [5][6]